Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Retatrutide in a diabetic rat kidney study
A 2026 rat study found a kidney HIF-1α change with retatrutide, but no statistically confirmed protection against tissue injury.
Rural GLP-1 chart review: 40 adults
A 40-person rural chart review linked tirzepatide or semaglutide use with improved A1c and several cardiometabolic measures.
GLP-1 drugs in schizophrenia: 7 trials
Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.
UK tirzepatide price rise shifted use
A million-person UK cohort linked a tirzepatide price increase with more semaglutide starts and treatment switching in self-paying care.
GLP-1 addiction study has no results yet
A planned semaglutide study will track addiction and social outcomes in 1,200 people, but it has no participant results or public protocol yet.
GLP-1 Hair Loss Review: What It Found
A 2026 GLP-1 hair loss review links shedding mainly to weight change, but the narrative evidence cannot prove direct drug causation.
GLP-1 Drugs and Spine Surgery Outcomes
A 23-study systematic review found procedure-specific, mostly observational associations rather than a clear benefit or harm in spine surgery.
GLP-1 Drugs and Substance Use Evidence
A 2026 review maps early semaglutide, exenatide, alcohol and tobacco findings without establishing incretin drugs as addiction treatments.
GLP-1 Drugs Cut Test-Meal Intake
A 2026 meta-analysis found GLP-1 therapy reduced intake by about 271 kcal at one test lunch, with real-world diet effects still uncertain.
GLP-1 Receptor Binding in Simulations
A 2026 computational study compared four GLP-1 receptor complexes, finding persistent structural differences without testing clinical outcomes.
Oral Semaglutide: 4-Month Study
A 70-person observational study linked four months of oral semaglutide care with lower weight, mostly through reduced fat mass.
Pediatric Obesity Drug Review: Gaps
A 2026 pediatric obesity drug review links adolescent semaglutide evidence with adult retatrutide research while leaving long-term safety open.